Literature DB >> 33651959

Effects of Atrial Fibrillation-Derived Exosome Delivery of miR-107 to Human Umbilical Vein Endothelial Cells.

Shuo Wang1,2, Liu Li3, Xitian Hu2, Tao Liu1, Wenyan Jiang1, Rubing Wu2, Yanchun Ren2, Mei Wang4.   

Abstract

The aim of this study was to explore the effects of atrial fibrillation (AF)-derived exosome delivery of miR-107 to human umbilical vein endothelial cells (HUVECs) and its related mechanisms. Exosomes were isolated from the plasma of patients with AF and healthy controls, followed by characterization. The expression levels of miR-320d, miR-103a-3p, and miR-107 were measured using real-time quantitative PCR (RT-qPCR). The dual-luciferase reporter gene was used to verify the downstream target of miR-107. Afterward, HUVECs were treated with AF-derived exosomes or transfected with miR-107 mimics. After cell culture, Cell Counting Kit-8, Transwell, and flow cytometry were used to determine cell viability, migration, and apoptosis and cell cycle phase. Finally, RT-qPCR was performed to examine the expression of related genes. NanoSight, transmission electron microscopy, and western blotting showed that exosomes were successfully isolated, and that AF-derived exosomes could be taken up by HUVECs. The expression of miR-107 was significantly higher in AF-derived exosomes than in normal exosomes (p < 0.05). USP14 was shown to be the direct target of miR-107. In addition, miR-107 mimics and AF-derived exosomes significantly suppressed cell viability and migration (p < 0.05) and enhanced cell apoptosis; they also increased G0/G1-phase cells and reduced S-phase cells. RT-qPCR showed that exosomal miR-107 overexpression significantly downregulated the expression of USP14 and Bcl2 (p < 0.05), whereas it markedly upregulated the expression of ERK2, FAK, and Bax (p < 0.05). AF-derived exosomes can deliver miR-107 to HUVECs, and exosomal miR-107 may regulate cell viability, migration, and apoptosis and cell cycle progression by mediating the miR-107/USP14 pathway.

Entities:  

Keywords:  atrial fibrillation; exosomes; human umbilical vein endothelial cells; miR-107; ubiquitin specific peptidase 14 (USP14)

Mesh:

Substances:

Year:  2021        PMID: 33651959     DOI: 10.1089/dna.2020.6356

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  6 in total

Review 1.  Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment.

Authors:  Hadi Sahrai; Erfan Rezazadeh-Gavgani; Yalda Yazdani; Amirreza Khalaji; Seyed Ziaeddin Rasihashemi; Parisa Lotfinejad
Journal:  Med Oncol       Date:  2022-09-07       Impact factor: 3.738

2.  Cardiac Fibroblasts Promote Ferroptosis in Atrial Fibrillation by Secreting Exo-miR-23a-3p Targeting SLC7A11.

Authors:  Dishiwen Liu; Mei Yang; Yajun Yao; Shanqing He; Youcheng Wang; Zhen Cao; Huiyu Chen; Yuntao Fu; Huafen Liu; Qingyan Zhao
Journal:  Oxid Med Cell Longev       Date:  2022-05-29       Impact factor: 7.310

Review 3.  Roles and mechanisms of exosomal non-coding RNAs in human health and diseases.

Authors:  Chen Li; Yu-Qing Ni; Hui Xu; Qun-Yan Xiang; Yan Zhao; Jun-Kun Zhan; Jie-Yu He; Shuang Li; You-Shuo Liu
Journal:  Signal Transduct Target Ther       Date:  2021-11-10

Review 4.  Extracellular Vesicles in Atrial Fibrillation-State of the Art.

Authors:  Grzegorz Procyk; Dominik Bilicki; Paweł Balsam; Piotr Lodziński; Marcin Grabowski; Aleksandra Gąsecka
Journal:  Int J Mol Sci       Date:  2022-07-08       Impact factor: 6.208

5.  Exosomes Isolated From Bone Marrow Mesenchymal Stem Cells Exert a Protective Effect on Osteoarthritis via lncRNA LYRM4-AS1-GRPR-miR-6515-5p.

Authors:  Xiuhui Wang; Zhuokai Li; Yin Cui; Xu Cui; Cheng Chen; Zhe Wang
Journal:  Front Cell Dev Biol       Date:  2021-05-28

Review 6.  Exosomes in atrial fibrillation: therapeutic potential and role as clinical biomarkers.

Authors:  Kun Xiang; Muhammad Akram; Walaa Fikry Elbossaty; Jinfu Yang; Chengming Fan
Journal:  Heart Fail Rev       Date:  2021-07-12       Impact factor: 4.654

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.